Heron Therapeuti (HRTX)vsNovartis AG ADR (NVS)
HRTX
Heron Therapeuti
$0.28
-8.44%
HEALTHCARE · Cap: $56.69M
NVS
Novartis AG ADR
$160.50
-0.19%
HEALTHCARE · Cap: $302.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 37845% more annual revenue ($57.36B vs $151.18M). NVS leads profitability with a 17.5% profit margin vs -22.5%. NVS earns a higher WallStSmart Score of 48/100 (D+).
HRTX
Avoid29
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
-67.6%
Fair Value
$95.76
Current Price
$160.50
$64.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
Trading at 9.5x book value
1.3% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 26.80 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.65 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 29/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?